LENISNA

LENISNA is a hybrid filler designed for aesthetic medicine, particularly for facial rejuvenation. It combines the immediate volumizing effects of hyaluronic acid (HA) with the long-term collagen-stimulating properties of Poly D,L-lactic acid (PDLLA). This unique formulation allows it to effectively address deep wrinkles, skin laxity, and significant tissue defects.

Composition and Mechanism of Action

The formulation of LENISNA includes 170 mg of PDLLA polylactic acid and 30 mg of non-cross-linked hyaluronic acid. The particle size ranges from 50 to 60 micrometers, which enables targeted application in subcutaneous or periosteal tissue. Upon injection, the HA provides an immediate filling effect, while the PDLLA microparticles stimulate collagen production approximately two weeks after treatment. This dual action results in both instant and gradual improvements in skin texture and volume.

Treatment Protocol

The recommended treatment protocol involves two to three sessions spaced 6-8 weeks apart. Each session begins with a thorough medical consultation followed by product preparation using sterile water for injection. Local anesthesia may be applied before injecting LENISNA into the desired areas using thin cannulas or needles. The results are visible immediately due to HA, while full benefits develop over several months as collagen production increases.

Longevity and Maintenance

One of LENISNA’s standout features is its durability; the effects can last over 24 months following the last treatment. To maintain these results, a single reminder treatment is recommended after this period. This extended duration makes LENISNA an appealing option for individuals seeking long-lasting facial rejuvenation without frequent interventions.

Indications for Use

LENISNA is particularly suitable for individuals aged 40 and above who exhibit clear signs of aging or require volume enhancement in sunken facial areas. It addresses various concerns such as folds in the skin, wrinkles, furrows, face drooping, and overall skin laxity.

Safety Profile

LENISNA has been clinically tested and holds FDA and CE certifications for safety. Its unique formulation minimizes risks associated with traditional fillers, such as lumps or migration of material post-injection.